Journals / Turkish Neurosurgery / 2014 / Cilt: 24 - Sayı: 1

Çin Popülasyonunda Karsinomatöz Menenjitli Hastaların Klinik Özellikleri: 4 Olgu Sunumu ve Literatürün Gözden Geçirilmesİ

Clinical Features of patients with Carcinomatous Meningitis in the Chinese population: Report of 4 Cases and Review of the Literature

Pages
13–18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Serum tumor biomarker determination, CSF cytology, and contrastenhanced MRI scan are essential in the diagnosis of CM

📌 3 Key Takeaways

🎯
Objective & Hypothesis:AIm: Carcinomatous meningitis (CM) is a rare neurological disorder.
📊
Key Findings & Data:We aim to promote the diagnostic efficiency of CM. mAterIAl and methOds: Four patients (1 male and 3 females) who had been diagnosed with CM from June 2007 to June 2009 in our department were included in this study.
💡
Conclusion & Impact:Serum tumor biomarker determination, CSF cytology, and contrastenhanced MRI scan are essential in the diagnosis of CM
🔬Design:Research Article
📍Scope:2007 Verileri
⚙️Variables:Domain Parameters

Abstract

AIm: Carcinomatous meningitis (CM) is a rare neurological disorder. We aim to promote the diagnostic efficiency of CM. mAterIAl and methOds: Four patients (1 male and 3 females) who had been diagnosed with CM from June 2007 to June 2009 in our department were included in this study. The mean age of those patients was 55.25 years. Clinical presentation, magnetic resonance imaging findings, cerebrospinal fluid (CSF) and serum tumor markers were examined. results: CM may present with acute or subacute onset of symptoms. Intracranial hypertension and meningeal irritation were common in patients with CM. Other symptoms included neck and occipital pain, unilateral lower limb weakness and abnormalities of the cranial nerves. Other unusual symptoms included impaired vision (2 cases), bilateral sensorineural hearing loss (1 case), and continuous roaring in both ears (1 case). MRI revealed contrast enhancement in the meninges in 3 cases. CSF cytology was positive for cancer cells in 2 cases. The survival of patients ranged from 18 days to 8 months. COnClusIOn: Patients with CM may present with a variety of symptoms. Serum tumor biomarker determination, CSF cytology, and contrastenhanced MRI scan are essential in the diagnosis of CM

Özet

AmAÇ: Karsinomatöz menenjit (KM) nadir bir nörolojik bozukluktur. KM için tanısal etkinliği arttırmayı amaçlıyoruz. yÖntem ve GereÇler: Haziran 2007 ile Haziran 2009 arasında bölümümüzde KM tanısı konan dört hasta (1 erkek ve 3 kadın) bu çalışmaya dahil edildi. Hastaların ortalama yaşı 55,25 yıldı. Klinik durum, manyetik rezonans görüntüleme bulguları, beyin omurilik sıvısı (BOS) ve serum tümör işaretleri incelendi.BulGulAr: KM akut veya subakut belirtilerle ortaya çıkabilir. İntrakraniyal hipertansiyon ve meningeal iritasyon bulguları KM hastalarında sıktı. Başka belirtiler arasında boyun ve oksipital ağrı, tek taraflı alt uzuv zayıflığı ve kraniyal sinir anormallikleri vardı. Diğer olağandışı belirtiler arasında görme bozukluğu (2 olgu), bilateral sensörinöral işitme kaybı (1 olgu) ve her iki kulakta sürekli uğuldama (1 olgu) vardı. MRG 3 olguda meninkslerin kontrast tuttuğunu gösterdi. BOS sitolojisi 2 olguda kanser hücreleri açısından pozitifti. Hastaların sağkalımı 18 gün ile 8 ay arasındaydı.sOnuÇ: KM hastaları çeşitli belirtilerle gelebilir. Serum tümör biyobelirteci saptanması, BOS sitolojisi ve kontrastlı MRG tarama KM tanısında şarttır

🔖

Cite This Article

DUAN, H., LI, M., SUN, X. (2014). Çin Popülasyonunda Karsinomatöz Menenjitli Hastaların Klinik Özellikleri: 4 Olgu Sunumu ve Literatürün Gözden Geçirilmesİ. Turkish Neurosurgery, Cilt: 24 - Sayı: 1, 13–18. https://ajindex.com/articles/405446

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (6)

  1. Aroney RS, Dalley DN, Chan WK, Bell DR, Levi JA: Meningeal cancer in small cell carcinoma of the lung. Am J Med 7: 26 -32, 1981
  2. Amer MH, Al-Sarraf M, Baker LH, Vaitkevicius VK: Malignant melanoma and central nervous system metastases: Incidence, diagnosis, treatment and survival. Cancer 42: 660-668, 1978
  3. Bowen CD, Von Burton G, Bargen RC, Madonia P, Zhang S, Toledo EG, Zweig R, Pant C: Carcinomatous meningitis secondary to transitional cell bladder cancer. South Med J 103: 809-812, 2010
  4. Bruna J, González L, Miró J, Velasco R, Gil M, Tortosa A: Leptomeningeal carcinomatosis: Prognostic implications of clinical and cerebrospinal fluid features. Cancer 115:381-389, 2009
  5. Bomgaars L, Chamberlin M, Poplack D: Leptomeningeal metastases. In Levin V (ed). Cancer in the Nervous System, 2nd. New York: Oxford University Press 2002:373-393
  6. Kosmas C, Tsavaris NB, Tsakonas G, Soukouli G, Gassiamis A, Mylonakis N, Karabelis A: Cerebrospinal fluid tumor marker levels in predicting response to treatment and survival of carcinomatous meningitis in patients with advanced breast cancer. Med Sci Monit 11(8): CR398-401, 2005 7. Fukuhara T, Saijo Y, Sakakibara T, Inoue A, Morikawa N, Kanamori M, Nakashima I, Nukiwa T: Successful treatment of carcinomatous meningitis with gefitinib in a patient with lung adenocarcinoma harboring a mutated EGF receptor gene. Tohoku J Med 214:359-363, 2008 8. Feyer P, Sautter-Bihl ML, Budach W, Dunst J, Haase W, Harms W, Sedlmayer F, Souchon R, Wenz F, Sauer R: DEGRO practical guidelines for palliative radiotherapy of breast cancer patients: Brain metastases and leptomeningeal carcinomatosis. Radiotherapy Strahlenther Onkol 186: 63-69, 2010 9. Hrrlinger U, Förschler H, Küker W, Meyermann R, Bamberg M, Dichgans J, Weller M: Leptomeningeal metastasis: Survival and prognostic factors in 155 patients. J Neurol Sci 223: 167-178, 2004 10. Hashimoto N, Imaizumi K, Honda T, Kawabe T, Nagasaka T, Shimokata K, Hasegawa Y: Successful re-treatment with gefitinib for carcinomatous meningitis as disease recurrence of non-small-cell lung cancer. Lung Cancer 53:387-390, 2006 11. Stemmlera HJ, Mengele K, Schmitt M, Harbeck N, Laessig D, Herrmann KA, Schaffer P, Heinemann V: Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing.metastatic breast cancer:a case report. Anti-Cancer Drugs 19: 832-836, 2008 12. Herrlinger U, Förschler H, Küker W, Meyermann R, Bamberg M, Dichgans J, Weller M: Leptomeningeal metastasis: Sur